Mackenzie Financial Corp Immuno Gen, Inc. Transaction History

Mackenzie Financial Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$12.46 - $29.95 $44,706 - $107,460	-3,588 Reduced 20.1%	14,265 $422,000
Q2 2023 Aug 03, 2023	BUY	$3.75 - $20.05 $4,500 - $24,060	1,200 Added 7.21%	17,853 $336,000
Q1 2023 Apr 24, 2023	SELL	$3.67 - $4.92 $327,547 - $439,110	-89,250 Reduced 84.28%	16,653 $63,000
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $40,349 - $55,957	8,868 Added 9.14%	105,903 $525,000
Q3 2022 Oct 07, 2022	SELL	$4.48 - $6.47 $4,488 - $6,482	-1,002 Reduced 1.02%	97,035 $464,000
Q2 2022 Aug 10, 2022	BUY	$3.15 - $5.76 $54,246 - $99,192	17,221 Added 21.31%	98,037 $441,000
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $14,356 - $25,207	3,370 Added 4.35%	80,816 $385,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $42,351 - $66,870	8,916 Added 13.01%	77,446 $575,000
Q3 2021 Nov 08, 2021	BUY	$5.02 - $6.59 $23,764 - $31,197	4,734 Added 7.42%	68,530 $389,000
Q2 2021 Aug 11, 2021	BUY	$5.79 - $8.6 $369,378 - $548,645	63,796 New	63,796 $420,000
Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $527,215 - $854,088	-81,110 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$3.7 - $7.66 $300,107 - $621,302	81,110 New	81,110 $523,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.